Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
tanj
May 2, 2024, 15:46 |
Insight
Tanja Obradovic: Battle with breast cancer is raging
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "Battle with breast…
May 2, 2024, 15:25 |
Blog
Tanja Obradovic: Interesting updates will be coming on ASCO 2024
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "ASCO 2024 is almost…
May 1, 2024, 10:55 |
Blog
Tanja Obradovic: The spotlight of FDA last week
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on LinkedIn:…
May 1, 2024, 09:57 |
Drugs
Tanja Obradovic: Dostarlimab chemotherapy in primary advanced or recurrent endometrial cancer
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON, shared on LinkedIn: "Further inroads of…
Apr 28, 2024, 18:45 |
Blog
Tanja Obradovic: Absolutely great meeting and productive exchange around trends and needs in today's pharma world
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared a post by Why Summits…
Apr 20, 2024, 08:16 |
Blog
Tanja Obradovic: One exciting novel approach is just about to enter clinical development
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn: "Cell…
Apr 17, 2024, 17:56 |
Blog
Tanja Obradovic: When during clinical development Medical Affairs Strategy should be started with the full force? Join for dialog and my presentation
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn:…
Apr 17, 2024, 11:33 |
Drugs
Tanja Obradovic: What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab?
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “What…
Apr 13, 2024, 07:17 |
Blog
Tanja Obradovic: Exploring the Potential of B Cell Activation in Cancer Immunotherapy: Insights from AT-1965 Phase 1/2 Study
Tanja Obradovic, Vice President of Scientific Affairs at ICON plc., shared a post on LinkedIn: "In fighting cancer…
Apr 12, 2024, 17:18 |
Drugs
Tanja Obradovic: Interesting statistics on the nature of licensing deals in pharmaceutics during last year
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “Interesting…
3
4
5
6
7
All:
74
Posts:
41 - 50
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube